Zydus Cadila gets USFDA nod for diabetes drug

Virendra Pandit Ahmedabad | Updated on January 17, 2018 Published on July 11, 2016


Cadila Healthcare Ltd (Zydus Cadila), on Monday, said it has received final approval from the US Food and Drug Administration (USFDA) for Nateglinide tablets USP.

With this, the Ahmedabad-based company will be able to market Nateglinide tablets USP in strengths of 60 mg and 120 mg, according to a release here.

The drug is an oral anti-diabetic agent used in the management of Type 2 diabetes mellitus and will be produced at the group’s formulations manufacturing facility at the Pharma SEZ in Ahmedabad.

The group now has more than 100 approvals and has so far filed nearly 270 ANDAs since the commencement of the filing process in FY 2003-04.

Published on July 11, 2016
This article is closed for comments.
Please Email the Editor